19 results on '"Jeng, Wen‐Juei"'
Search Results
2. Highlights from the 2023 International Meeting on the Molecular Biology of Hepatitis B virus.
- Author
-
Allweiss L, Cohen C, Dias J, Fumagalli V, Guo H, Harris JM, Hu J, Iannacone M, Isogawa M, Jeng WJ, Kim KH, Kramvis A, Li W, Lucifora J, Muramatsu M, Neuveut C, Ploss A, Pollicino T, Protzer U, Tan A, Tanaka Y, Tu T, Tsukuda S, Thimme R, Urban S, Watashi K, Yuan Z, Yeh SH, McKeating JA, and Revill PA
- Subjects
- Humans, Molecular Biology, Japan, Hepatitis D virology, Host-Pathogen Interactions immunology, Host-Pathogen Interactions genetics, Hepatitis B virus genetics, Hepatitis B virus physiology, Hepatitis B virus immunology, Virus Replication, Hepatitis Delta Virus genetics, Hepatitis Delta Virus physiology, Hepatitis B virology, Hepatitis B immunology
- Abstract
Since its discovery in 1965, our understanding of the hepatitis B virus (HBV) replication cycle and host immune responses has increased markedly. In contrast, our knowledge of the molecular biology of hepatitis delta virus (HDV), which is associated with more severe liver disease, is less well understood. Despite the progress made, critical gaps remain in our knowledge of HBV and HDV replication and the mechanisms underlying viral persistence and evasion of host immunity. The International HBV Meeting is the leading annual scientific meeting for presenting the latest advances in HBV and HDV molecular virology, immunology, and epidemiology. In 2023, the annual scientific meeting was held in Kobe, Japan and this review summarises some of the advances presented at the Meeting and lists gaps in our knowledge that may facilitate the development of new therapies.
- Published
- 2024
- Full Text
- View/download PDF
3. Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
- Author
-
Jeng WJ, Chien RN, and Liaw YF
- Subjects
- Humans, Hepatitis B e Antigens, Prognosis, Liver Cirrhosis, Hepatitis B virus genetics, Antiviral Agents therapeutic use, Hepatitis B, Hepatitis B, Chronic complications, Hepatitis B, Chronic drug therapy
- Published
- 2024
- Full Text
- View/download PDF
4. Reply: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect, or residual confounding?
- Author
-
Liaw YF, Jeng WJ, and Chien RN
- Subjects
- Humans, Liver Cirrhosis drug therapy, Hepatitis B virus genetics, Antiviral Agents therapeutic use, DNA, Viral, Hepatitis B e Antigens, Hepatitis B Surface Antigens, Hepatitis B drug therapy, Hepatitis B, Chronic drug therapy
- Published
- 2024
- Full Text
- View/download PDF
5. Letter to the Editor: Proper monitoring instead of expanding treatment for improving the prognosis of indeterminate phase hepatitis B patients.
- Author
-
Jeng WJ and Liaw YF
- Subjects
- Humans, Prognosis, Hepatitis B virus, Hepatitis B diagnosis, Hepatitis B drug therapy, Hepatitis B, Chronic diagnosis, Hepatitis B, Chronic drug therapy
- Published
- 2023
- Full Text
- View/download PDF
6. Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection.
- Author
-
Liu YC, Jeng WJ, and Chien RN
- Subjects
- Humans, Hepatitis B, Chronic drug therapy, Hepatitis B
- Published
- 2023
- Full Text
- View/download PDF
7. Hepatitis B.
- Author
-
Jeng WJ, Papatheodoridis GV, and Lok ASF
- Subjects
- Adult, Humans, Hepatitis B Surface Antigens, DNA, Viral, Hepatitis B virus, Antiviral Agents therapeutic use, Liver Cirrhosis drug therapy, Immunoglobulin M, Hepatitis B diagnosis, Hepatitis B drug therapy, Hepatitis B prevention & control, Hepatitis B, Chronic diagnosis, Hepatitis B, Chronic drug therapy, Hepatitis B, Chronic prevention & control, Liver Neoplasms drug therapy
- Abstract
Hepatitis B virus (HBV) infection is a major public health problem, with an estimated 296 million people chronically infected and 820 000 deaths worldwide in 2019. Diagnosis of HBV infection requires serological testing for HBsAg and for acute infection additional testing for IgM hepatitis B core antibody (IgM anti-HBc, for the window period when neither HBsAg nor anti-HBs is detected). Assessment of HBV replication status to guide treatment decisions involves testing for HBV DNA, whereas assessment of liver disease activity and staging is mainly based on aminotransferases, platelet count, and elastography. Universal infant immunisation, including birth dose vaccination is the most effective means to prevent chronic HBV infection. Two vaccines with improved immunogenicity have recently been approved for adults in the USA and EU, with availability expected to expand. Current therapies, pegylated interferon, and nucleos(t)ide analogues can prevent development of cirrhosis and hepatocellular carcinoma, but do not eradicate the virus and rarely clear HBsAg. Treatment is recommended for patients with cirrhosis or with high HBV DNA levels and active or advanced liver disease. New antiviral and immunomodulatory therapies aiming to achieve functional cure (ie, clearance of HBsAg) are in clinical development. Improved vaccination coverage, increased screening, diagnosis and linkage to care, development of curative therapies, and removal of stigma are important in achieving WHO's goal of eliminating HBV infection by 2030., Competing Interests: Declaration of interests W-JJ has served as advisor and lecturer for Bristol Myers Squibb and Gilead; and received grants for research and attendance of meetings from Chang Gung Medical Foundation and National Science Council of Taiwan. GVP has served as advisor and lecturer for Amgen, Gilead, GlaxoSmithKline, Ipsen, Janssen, Novo Nordisk, Roche, and Takeda; received support for attendance of meetings from Gilead Sciences, Ipsen, Janssen, Merck Sharp & Dohme, Novo Nordisk, Roche, and Takeda; and received research grants from Gilead. ASFL has received research grants from Bristol Myers Squibb, Gilead, and TARGET Pharma, and royalties from Wolters Kluwer (UpToDate) and Wiley (textbooks); and served as advisor and consultant for Ambys, Amgen, Arbutus, Chroma, CLEAR-B, Eli Lilly, Enanta, Enochian, GlaxoSmithKline, GNI, Huahui, Janssen, TARGET, and Virion. Editorial note: the Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
8. What will it take to cure hepatitis B?
- Author
-
Jeng WJ and Lok ASF
- Subjects
- Humans, Hepatitis B Surface Antigens, Antiviral Agents therapeutic use, Hepatitis B virus genetics, DNA, Viral, Neoplasm Recurrence, Local, DNA, Circular, Hepatitis B Core Antigens, Hepatitis B, Chronic, Carcinoma, Hepatocellular drug therapy, Hepatitis C, Chronic drug therapy, Liver Neoplasms drug therapy, Hepatitis B drug therapy
- Abstract
The current treatment of chronic HBV infection, pegylated interferon-α (pegIFNα) and nucleos(t)ide analog (NA), can suppress HBV replication, reverse liver inflammation and fibrosis and reduce the risks of cirrhosis, HCC, and HBV-related deaths, but relapse is common when the treatment is stopped before HBsAg loss. There have been major efforts to develop a cure for HBV, defined as sustained HBsAg loss after a finite course of therapy. This requires the suppression of HBV replication and viral protein production and the restoration of immune response to HBV. Direct-acting antivirals targeting virus entry, capsid assembly, viral protein production and secretion are in clinical trials. Immune modulatory therapies to stimulate adaptive or innate immunity and/or to remove immune blockade are being tested. NAs are included in most and pegIFNα in some regimens. Despite the combination of 2 or more therapies, HBsAg loss remains rare in part because HbsAg can be derived not only from the covalently closed circular DNA but also from the integrated HBV DNA. Achievement of a functional HBV cure will require therapies to eliminate or silence covalently closed circular DNA and integrated HBV DNA. In addition, assays to differentiate the source of circulating HBsAg and to determine HBV immune recovery, as well as standardization and improvement of assays for HBV RNA and hepatitis B core-related antigen, surrogate markers for covalently closed circular DNA transcription, are needed to accurately assess response and to target treatments according to patient/disease characteristics. Platform trials will allow the comparison of multiple combinations and channel patients with different characteristics to the treatment that is most likely to succeed. Safety is paramount, given the excellent safety profile of NA therapy., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.)
- Published
- 2023
- Full Text
- View/download PDF
9. A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B.
- Author
-
Yuen MF, Chen CY, Liu CJ, Jeng WJ, Elkhashab M, Coffin CS, Kim W, Greenbloom S, Ramji A, Lim YS, Kim YJ, Fung SK, Kim DJ, Jang JW, Lee KS, Iyer RP, Macfarlane C, Jackson K, Locarnini SA, Chan HLY, and Afdhal NH
- Subjects
- Humans, Hepatitis B Surface Antigens, DNA, Viral, Tenofovir therapeutic use, Antiviral Agents adverse effects, Hepatitis B virus genetics, Hepatitis B e Antigens, RNA, Treatment Outcome, Hepatitis B, Chronic, Hepatitis B drug therapy
- Abstract
Background/aims: Novel agents acting against hepatitis B virus (HBV) are needed to improve HBsAg seroclearance or termed as 'functional cure'. Inarigivir (retinoic acid-inducible gene I agonist) has immunomodulatory and direct antiviral actions against HBV. We aimed to determine the safety and efficacy of Inarigivir for the treatment of HBV infection., Patients/methods: 80 treatment-naïve patients were randomized in 4 ascending dose cohorts to receive 12 weeks of Inarigivir 25, 50, 100, 200 mg or placebo in a ratio of 4:1. All patients were then given tenofovir for another 12 weeks., Results: Least squares (LS) mean reductions in HBV DNA from baseline increased with higher doses of Inarigivir (0.6116 in 25 mg and 1.5774 in 200 mg groups vs. 0.0352 in placebo group) (95% CI 0.9518-0.2011 and 1.921-1.1634 respectively). LS mean changes in HBV RNA and HBsAg from baseline ranged from -0.3856 to -0.5794 versus -0.1474 and -0.0956 to -0.1818 versus +0.0026 in Inarigivir-treated versus placebo groups respectively. During the tenofovir-treated period, LS mean reductions in HBsAg in the Inarigivir-treated groups ranged from 0.1709 to 0.3529 versus 0.1984 in the placebo group. Inarigivir-treated groups showed mean reductions in ALT from baseline between 23.3 and 33.8 versus 0.7 U/L in the placebo group. Treatment-emergent adverse events related to Inarigivir and placebo occurred in 4.7% and 6.3% patients respectively., Conclusions: Twelve-week Inarigivir up to 200 mg dose was associated with a reduction of HBV DNA, HBV RNA and antigen levels. A trend for greater HBsAg reduction was observed in Inarigivir pre-treated patients after switching to tenofovir., (© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
10. Unsolved issues in treatment for grey zone chronic hepatitis B patients.
- Author
-
Jeng WJ and Chien RN
- Subjects
- Antiviral Agents therapeutic use, Hepatitis B Surface Antigens, Humans, Hepatitis B drug therapy, Hepatitis B, Chronic drug therapy
- Published
- 2022
- Full Text
- View/download PDF
11. Serum soluble programmed death-1 levels predict the spontaneous HBeAg seroclearance in chronic hepatitis B.
- Author
-
Chu YJ, Jeng WJ, Pan MH, Hu HH, Luo WS, Su CY, Chiang CT, Jen CL, Chen CJ, and Yang HI
- Subjects
- DNA, Viral, Hepatitis B Surface Antigens, Hepatitis B e Antigens, Hepatitis B virus genetics, Humans, Hepatitis B, Hepatitis B, Chronic, Liver Neoplasms
- Abstract
Background and Aims: In chronic hepatitis B virus (HBV) infection, earlier seroclearance of hepatitis B e antigen (HBeAg) is associated with more favorable outcomes. Soluble programmed cell death 1 (sPD-1) has been implicated in higher viral load and hepatocellular carcinoma. We investigated the association between sPD-1 levels and spontaneous HBeAg seroclearance., Methods: Baseline serum samples from 488 HBeAg-seropositive patients in the REVEAL-HBV cohort were tested for sPD-1 levels. Among them, 329 with available follow-up serum samples were further assayed. Multivariate Cox regression analysis was used to estimate the adjusted rate ratio (aRR) and 95% confidence interval (CI) with adjustment of host and viral factors. The 66th percentile and an annual reduction of ≥ 10% were used as the cut-off point for baseline sPD-1 levels (high/low) and sPD-1 trajectory (decline/no decline), respectively., Results: Lower baseline sPD-1 levels [aRR (95% CI): 2.19 (1.47-3.27)] and long-term decline in sPD-1 levels [aRR (95% CI): 4.08 (2.79-5.97)] were both independent predictors for HBeAg seroclearance. However, further stratification analysis by HBV genotype showed that lower baseline sPD-1 levels were significantly associated with HBeAg seroclearance only in genotype C infection [aRR (95% CI): 4.47 (2.38-8.37)] but not in genotype B infection. On the other hand, long-term decline in sPD-1 levels was predictive for HBeAg seroclearance regardless of HBV genotype with aRR (95% CI) of 4.62 (2.71-7.88) and 2.95 (1.68-5.17), respectively, for genotypes B and C., Conclusion: Serum sPD-1 levels may serve as a novel immunological predictor for spontaneous HBeAg seroclearance in patients with chronic hepatitis B., (© 2022. Japanese Society of Gastroenterology.)
- Published
- 2022
- Full Text
- View/download PDF
12. Hepatitis B Co-Infection Has Limited Impact on Liver Stiffness Regression in Chronic Hepatitis C Patients Treated with Direct-Acting Antivirals.
- Author
-
Hsu CE, Liu YC, Cheng YT, Jeng WJ, Chien RN, Lin CY, Tai DI, and Sheen IS
- Subjects
- Antiviral Agents therapeutic use, Hepatitis B virus, Humans, Male, Coinfection drug therapy, Hepatitis B, Hepatitis C drug therapy, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy
- Abstract
Introduction: High sustained virological response (SVR) rate (>95%) and liver stiffness regression can be achieved with direct acting antivirals treatment (DAA) in patients with chronic hepatitis C virus (CHC) infection. Reactivation of hepatitis B virus (HBV) was reported during DAA treatment in patients co-infected with HBV, although its impact on liver stiffness remains unknown. This study aims to investigate whether the liver stiffness (LSM) regression is different between HBV/HCV co-infected and mono-HCV-infected patients. Materials and Methods: CHC patients with/without HBV co-infection who received DAA treatment and achieved SVR12 between March 2015 and December 2019 in Chang Gung Memorial Hospital, Linkou branch were prospectively enrolled. LSM was assessed by transient elastography (TE, Fibroscan) at baseline and after SVR. Propensity score matching (PSM) at 3:1 ratio, adjusted for age, gender, pre-DAA alanine aminotransferase (ALT), platelet count, and LSM, between CHC with and without HBV co-infection, was performed before further analysis. Results: Among 906 CHC patients enrolled, 52 (5.7%) patients had HBV/HCV co-infection. Patients with HBV/HCV co-infection were of younger age (61.8 vs. 63.2, p = 0.31), with a higher proportion of males (53.8% vs. 38.9%, p = 0.03), and lower pretreatment LSM level (8.15 vs. 10.2 kPa, p = 0.09), while other features were comparable. After PSM, patients with HBV/HCV co-infection had insignificantly lower LSM regression compared to mono-HCV-infected patients (−0.85 kPa vs. −1.65 kPa, p = 0.250). Conclusions: The co-infection of HBV among CHC patients has limited impact on liver stiffness regression after successful DAA treatment.
- Published
- 2022
- Full Text
- View/download PDF
13. Highly significant differences in HBsAg kinetics among patients with two types of hepatitis B flare, with and without retreatment.
- Author
-
Jeng WJ, Liu YC, Peng CW, Chien RN, and Liaw YF
- Subjects
- Antiviral Agents therapeutic use, DNA, Viral, Hepatitis B Surface Antigens, Hepatitis B e Antigens therapeutic use, Hepatitis B virus genetics, Humans, Kinetics, Retreatment, Symptom Flare Up, Hepatitis B drug therapy, Hepatitis B, Chronic drug therapy
- Abstract
Background: Off-therapy hepatitis flare may be detrimental or, conversely, facilitate hepatitis B surface antigen (HBsAg) decline. Retreatment decisions are crucial., Methods: HBsAg was quantified before and during flares, at peak/retreatment start and at Months 6 and 12 in 336 entecavir/tenofovir-retreated and 105 non-retreated hepatitis B e antigen (HBeAg)-negative patients. Increasing HBsAg during ALT flare defined a 'virus-dominating flare' and decreasing HBsAg a 'host-dominating flare'., Results: Two hundred and eighty-eight retreated patients with a virus-dominating flare showed greater 1 year HBsAg decline (-1.0 versus -0.01 log10 IU/mL; P < 0.0001), more frequent rapid decline (69.8% versus 8.3%; P < 0001) and higher 3 year incidence of HBsAg < 100 IU/mL (32% versus 12%; P = 0.026) than 48 patients with a host-dominating flare, of whom 16 (33.3%) showed 3.8-fold (2 to 52-fold) HBsAg rebound on retreatment (versus 2/288; P < 0.0001). Compared with non-retreated controls, 1 year HBsAg decline was greater (-1.0 versus -0.47 log10 IU/mL; P < 0.0001) and faster (69.8% versus 42.5%; P < 0.0001) in patients with a virus-dominating flare, whereas 1 year HBsAg decline (-0.01 versus -0.16 log10 IU/mL) and 3 year HBsAg loss rate (0% versus 21%; P = 0.009) were lower in patients with a host-dominating flare., Conclusions: Entecavir/tenofovir retreatment effectively decreases HBsAg level in patients with a virus-dominating flare but is ineffective/worse in patients with a host-dominating flare. These results support the use of combined HBsAg/ALT kinetics for the decision to retreat patients with a virus-dominating flare and withhold retreatment for patients with a host-dominating flare., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
14. Integrated model for end-stage liver disease maybe superior to some other model for end-stage liver disease-based systems in addition to Child-Turcotte-Pugh and albumin-bilirubin scores in patients with hepatitis B virus-related liver cirrhosis and spontaneous bacterial peritonitis.
- Author
-
Chen PC, Chen BH, Huang CH, Jeng WJ, Hsieh YC, Teng W, Chen YC, Ho YP, Sheen IS, and Lin CY
- Subjects
- Adult, Aged, Area Under Curve, Bacterial Infections complications, Bacterial Infections diagnosis, Bilirubin blood, Biomarkers blood, End Stage Liver Disease complications, End Stage Liver Disease diagnosis, End Stage Liver Disease virology, Female, Follow-Up Studies, Hepatitis B blood, Hepatitis B complications, Hospital Mortality, Humans, Liver Cirrhosis complications, Liver Cirrhosis diagnosis, Liver Cirrhosis virology, Male, Middle Aged, Peritonitis complications, Peritonitis diagnosis, Peritonitis microbiology, ROC Curve, Retrospective Studies, Serum Albumin metabolism, Taiwan epidemiology, Bacterial Infections mortality, Clinical Decision Rules, End Stage Liver Disease mortality, Hepatitis B mortality, Liver Cirrhosis mortality, Peritonitis mortality, Severity of Illness Index
- Abstract
Objectives: For mortality prediction of spontaneous bacterial peritonitis (SBP) in patients with cirrhosis, no direct comparisons have been made among the eight models, Child-Turcotte-Pugh (CTP) score, model for end-stage liver disease (MELD), MELD-Na, integrated MELD (iMELD) score, MELD to sodium (MESO) index, modification of the MELD scoring system (Refit MELD), Refit MELD-Na and Albumin-Bilirubin (ALBI) score., Materials and Methods: Between January 2005 and July 2017, 314 patients who met the criteria for liver cirrhosis with the first episode of SBP were enrolled in this retrospective study. Clinical and laboratory data were obtained at diagnosis. Patients were followed up until February 2018 or death., Results: Patients were predominantly middle-aged male. Hepatitis B virus (HBV) infection accounted for the majority of the etiologies (41.7%) with 33.6% of the patients received antivirals. The in-hospital mortality rate was 39.8%. The cumulative 3-month and 6-month mortality rates were 51.6 and 60.2%, respectively. For patients with HBV related, not hepatitis C virus or alcohol related, liver cirrhosis, iMELD had the highest area under receiver operating characteristic curve (AUC) and was significantly superior to MELD, MESO, and Refit MELD in addition to CTP and ALBI scores in predicting 3-month and 6-month mortality., Conclusion: For patients with HBV-related liver cirrhosis and SBP, iMELD had the highest AUC among these eight models and was significantly superior to MELD, MESO, and Refit MELD in addition to CTP and ALBI scores in predicting 3-month and 6-month mortalities.
- Published
- 2019
- Full Text
- View/download PDF
15. Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression.
- Author
-
O'Brien TR, Yang HI, Groover S, and Jeng WJ
- Subjects
- Disease Progression, Genetic Predisposition to Disease genetics, Hepatitis B pathology, Hepatitis C pathology, Humans, Hepatitis B genetics, Hepatitis B therapy, Hepatitis C genetics, Hepatitis C therapy, Immunity, Active genetics, Remission, Spontaneous
- Abstract
Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections can lead to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Over the past decade, studies of individuals infected with these viruses have established genetic associations with the probability of developing a chronic infection, risk of disease progression, and likelihood of treatment response. We review genetic and genomic methods that have been used to study risk of HBV and HCV infection and patient outcomes. For example, genome-wide association studies have linked a region containing the interferon lambda genes to spontaneous and treatment-induced clearance of HCV. We review the genetic variants associated with HCV and HBV infection, and how these variants affect specific expression or activities of their products. Further studies of these variants could provide insights into risk factors for and mechanisms of chronic infection and disease progression, as well as new strategies for treatment., (Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
16. A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off‐therapy relapse: An observational study.
- Author
-
Peng, Chien‐Wei, Jeng, Wen‐Juei, Yang, Hwai‐I, Liu, Yen‐Chun, Chien, Rong‐Nan, and Liaw, Yun‐Fan
- Subjects
- *
CHRONIC hepatitis B , *HEPATITIS B , *TENOFOVIR , *PROPENSITY score matching , *DISEASE relapse , *SCIENTIFIC observation - Abstract
Background and Aim: In HBeAg negative chronic hepatitis B (CHB) patients, clinical relapse (CR) occurs more frequently, much earlier and often more severely after stopping tenofovir (TDF) and other nucleos(t)ide analogues (Nucs) than after stopping entecavir (ETV). It is unknown whether off‐Nuc hepatitis flare can be alleviated by switching from one Nuc to another. Methods: HBeAg‐negative CHB patients who had stopped Nuc according to the APASL stopping rule and had been followed‐up for > 48 weeks after Nuc cessation were recruited. Patients were classified as four groups: ETV monotherapy (mono‐ETV), TDF monotherapy (mono‐TDF), switched to ETV (switch‐ETV), and switched to TDF (switch‐TDF). Both switch groups had switched to the replacement Nuc > 12 weeks prior to end of therapy. Propensity score matching (PSM) was performed to minimize confounders among groups. Cox regression analysis was used to identify risks factors for off‐Nuc CR and flares. Results: A total of 1309 patients (1022 mono‐ETV, 219 mono‐TDF, 40 switch‐ETV and 28 switch‐TDF) were enrolled. The median time to CR was 39, 13, 38 and 14 weeks in mono‐ETV, mono‐TDF, switch‐ETV and switch‐TDF respectively (P < 0.001). After PSM, the mono‐ETV (adjusted HR: 0.39, P < 0.001) and switch‐ETV patients (adjusted HR: 0.41, P = 0.003) had both significantly later occurrence and lower rates of CR and flare. Conclusion: In summary, the incidence and timing of CR was determined by ETV or TDF in the last 3 months prior to end of treatment. Patients treated with non‐ETV‐Nuc switched to ETV > 12 weeks before end of the original Nuc therapy may reduce/defer CR. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Highly significant differences in HBsAg kinetics among patients with two types of hepatitis B flare, with and without retreatment.
- Author
-
Jeng, Wen-Juei, Liu, Yen-Chun, Peng, Chien-Wei, Chien, Rong-Nan, and Liaw, Yun-Fan
- Subjects
- *
CHRONIC hepatitis B , *HEPATITIS B , *HEPATITIS associated antigen - Abstract
Background: Off-therapy hepatitis flare may be detrimental or, conversely, facilitate hepatitis B surface antigen (HBsAg) decline. Retreatment decisions are crucial.Methods: HBsAg was quantified before and during flares, at peak/retreatment start and at Months 6 and 12 in 336 entecavir/tenofovir-retreated and 105 non-retreated hepatitis B e antigen (HBeAg)-negative patients. Increasing HBsAg during ALT flare defined a 'virus-dominating flare' and decreasing HBsAg a 'host-dominating flare'.Results: Two hundred and eighty-eight retreated patients with a virus-dominating flare showed greater 1 year HBsAg decline (-1.0 versus -0.01 log10 IU/mL; P < 0.0001), more frequent rapid decline (69.8% versus 8.3%; P < 0001) and higher 3 year incidence of HBsAg < 100 IU/mL (32% versus 12%; P = 0.026) than 48 patients with a host-dominating flare, of whom 16 (33.3%) showed 3.8-fold (2 to 52-fold) HBsAg rebound on retreatment (versus 2/288; P < 0.0001). Compared with non-retreated controls, 1 year HBsAg decline was greater (-1.0 versus -0.47 log10 IU/mL; P < 0.0001) and faster (69.8% versus 42.5%; P < 0.0001) in patients with a virus-dominating flare, whereas 1 year HBsAg decline (-0.01 versus -0.16 log10 IU/mL) and 3 year HBsAg loss rate (0% versus 21%; P = 0.009) were lower in patients with a host-dominating flare.Conclusions: Entecavir/tenofovir retreatment effectively decreases HBsAg level in patients with a virus-dominating flare but is ineffective/worse in patients with a host-dominating flare. These results support the use of combined HBsAg/ALT kinetics for the decision to retreat patients with a virus-dominating flare and withhold retreatment for patients with a host-dominating flare. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
18. Hepatitis B Virus DNA Level Predicts Hepatic Decompensation in Patients With Acute Exacerbation of Chronic Hepatitis B.
- Author
-
Jeng, Wen–Juei, Sheen, I–Shyan, and Liaw, Yun–Fan
- Subjects
HEPATITIS B virus ,DNA ,HEPATITIS B ,HEPATITIS associated antigen ,VIRAL load ,ALANINE aminotransferase ,RECEIVER operating characteristic curves ,LOGISTIC regression analysis ,PATIENTS - Abstract
Background & Aims: Acute exacerbations of chronic hepatitis B virus (HBV) infection can lead to hepatic decompensation. It is important to identify factors that predict the development of hepatic decompensation during exacerbation so that antiviral therapy can be initiated immediately. Methods: Acute exacerbation, defined by an abrupt increase in alanine aminotransferase (ALT) levels to >5-fold the upper limit of normal, occurred in 110 hepatitis B e antigen (HBeAg)-seropositive non-cirrhotic patients (138 episodes). The patients were monitored every 1 to 2 weeks for serum levels of ALT, bilirubin, albumin, and prothrombin. Sex, age, HBV genotype, ALT level, HBV viral load, and the causes (spontaneous or relapse from antiviral treatment) of exacerbation were included in multivariate logistic regression analyses. The receiver operating characteristic curve was used to identify the optimal cut-off value of serum HBV DNA level to identify patients at risk for decompensation. Results: Seven of the 138 episodes of acute exacerbation (5.1%) resulted in hepatic decompensation; serum HBV DNA level was the only significant risk factor (P = .003). The area under the receiver operating characteristic curve was 88.6% (P < .001). A serum HBV DNA cut-off value of 1.55 × 10
9 copies/mL predicted decompensation with a sensitivity of 85.7%, a specificity of 85.5%, a negative prediction value of 99.1%, and positive prediction value of 24.0%. Conclusions: During acute exacerbation of HBeAg-positive chronic hepatitis B, a serum HBV DNA cut-off value of 1.55 × 109 copies/mL can be used to identify patients in need of immediate antiviral therapy. [Copyright &y& Elsevier]- Published
- 2010
- Full Text
- View/download PDF
19. Serum HBsAg kinetics in clinical prediction.
- Author
-
Jeng, Wen-Juei and Liaw, Yun-Fan
- Subjects
- *
HEPATITIS associated antigen , *HEPATITIS B treatment , *ANTIGENS , *CLINICAL prediction rules , *HEPATITIS B , *PHYSIOLOGY - Abstract
The article presents a review of the article, "``The role of quantitative hepatitis B surface antigen revisited," along with a discussion on the role played by Serum HBsAG in the clinical prediction of Hepatitis B virus. Details related to the medical studies used, along with the findings of the study are discussed.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.